Features of MenC conjugate vaccine
- developed using same technology used in the development of Hib vaccine
- the vaccine induces a T-cell dependent antibody response and immunological memory - it is protective in children under 2 years of age
- carrier proteins used in MenC conjugate vaccines are tetanus toxoid or variant diphtheria toxin (CRM197)
- the vaccine should be reconstituted immediately before use with the dilutent supplied by the manufacturer - once the vaccine has been reconstituted then it must be used within one hour
- administered as a intramuscular or deep subcutaneous injection - in patients with bleeding disorders or thrombocytopaenia then the vaccine may be given subcutaneously
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.